GlomCon Hawaii 2025
September 22 - 25, 2025
O'ahu, HI
Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti‑inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study
Sparsentan in IgAN: Spotlight on Phase 2 and OLE Clinical Trial Results Evaluating Concomitant Use With SGLT2i
Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
19th International Conference on Endothelin (ET-19)
September 21 - 24, 2025
Charleston
American Society of Nephrology (ASN) Kidney Week 2025
November 6 - 9, 2025
Houston
International Symposium on IgA Nephropathy (IIgANN)
September 17 - 20, 2025
Czech Republic
Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial
Clinical Study Outcomes in IgA Nephropathy: A Systematic Literature Review and Narrative Synthesis
Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX
Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
15th International Podocyte Conference and 2025 ISGD Meeting
June 10 - 13, 2025
Germany
Sparsentan Reversibly Decreases Mesangial IgA Deposition in gddY Mice: A Possible Role for Mesangial-Cell -Surface Autoantigen Expression